After receiving approval from the Ministry of Food and Drug Safety for CT-P59 Phase 2 and Phase 3 trials in September

After receiving approval from the Ministry of 룸사롱 Food and Drug Safety for CT-P59 Phase 2 and Phase 3 trials in September, the company has been conducting Phase 2 clinical trials in major medical institutions in Korea, as well as in the U.S., Romania, and Spain. "We are focusing on the effectiveness and safety of CT-P59 in patients with mild and moderate symptoms," said Seltrion. "We have successfully secured 327 subjects, 강남룸사롱 more than the 300 clinical second-phase patients originally planned." Seltrion classified the subjects in Phase 2 clinical trials as placebo, low-concentration, and high-concentration. Through data analysis, the effectiveness and safety of CT-P59 and proper dosage will be checked. "We plan to draw up an interim result on phase 2 clinical trials as soon as possible, consult closely with the Ministry of Food and Drug Safety and other related agencies, 서울룸사롱 and apply for conditional permission for CT-P59, the company said.